Catherine M. Kelly

Family Medicine

2301 Robeson St
Fayetteville, NC 28305

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 09, 2025

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: November 05, 2025

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 15, 2025

Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer.

Spatial analyses implicate high stromal tumour-infiltrating CD8+ lymphocytes as a negative predictive marker for chemotherapy in estrogen receptor-positive breast cancer.

Journal: Nature communications

Published: September 27, 2025

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Journal: JCO precision oncology

Published: September 02, 2025

Understanding the needs and experiences of young cancer patients, caregivers and healthcare professionals in the UK following childhood fertility tissue preservation (FTP): a qualitative study informed by patient and public involvement and engagement.

Understanding the needs and experiences of young cancer patients, caregivers and healthcare professionals in the UK following childhood fertility tissue preservation (FTP): a qualitative study informed by patient and public involvement and engagement.

Journal: BMJ open

Published: July 28, 2025

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

Journal: NPJ breast cancer

Published: June 29, 2025

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

Journal: JCO precision oncology

Published: April 10, 2025

TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis.

TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis.

Journal: Acta oncologica (Stockholm, Sweden)

Published: February 11, 2025

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 03, 2025

Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO.

Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO.

Journal: JCO oncology practice

Published: November 12, 2024

CTRIAL-IE (ICORG) 15-34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland.

CTRIAL-IE (ICORG) 15-34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland.

Journal: Irish journal of medical science

Published: August 27, 2024

Showing 1-12 of 89

Last Updated: 09/26/2026